ASH: Gilead touts 'astounding' Yescarta survival results at 3 years

ASH: Gilead touts 'astounding' Yescarta survival results at 3 years

Source: 
Fierce Pharma
snippet: 

How long can a single infusion of Gilead Sciences CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, the company showed Saturday.